EGFR and neoplasm: Although a previous study of preoperative gefitinib in stage I NSCLC found an association between EGFR mutation status and decreasing tumor diameter following therapy, it similarly demonstrated a more muted response to therapy than expected (3/6 patients) as well as identified response in a patient with EGFR wildtype NSCLC but with high EGFR copy number [15].